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Abstract
Background: Osteonecrosis of the femoral head is a common complication of high-dose glucocorticoid treatment.
Intravascular thrombosis is thought to be associated with the ischemic state of the femoral head. Plasminogen
activator inhibitor-1 (PAI-1) is an adipokine, which are physiologically active substances secreted from visceral and
subcutaneous adipocytes. PAI-1 suppresses fibrinolysis by binding tissue-type plasminogen activator. Several reports
have described the relationship between PAI-1 and steroid-induced osteonecrosis of the femoral head, and the
preventive effects of lipid-lowering agents (statins) against steroid-induced osteonecrosis of the femoral head. We
previously reported that adipokines and dexamethasone induced PAI-1 secretion from bone marrow adipocytes.
The purpose of the present study is to examine the effects of simvastatin on PAI-1 secretion from human bone
marrow adipocytes in vitro.
Methods: Primary bone marrow adipocytes were extracted from collagenase-treated bone marrow fluid obtained
from the femoral necks of 40 patients (6 men, 34 women; age range, 52-81 years) undergoing hip joint
replacement surgery. After suspended culture with or without dexamethasone or simvastatin, PAI-1 mRNA
expression was assessed by real-time RT-PCR. Total PAI-1 protein secretion in culture medium was assessed by
enzyme-linked immunosorbent assay.
Results: PAI-1 mRNA expression was up-regulated by 388% (P = 0.002) with dexamethasone, and down-regulated by
45% (P = 0.002) with simvastatin, as compared to control levels. Dexamethasone increased total PAI-1 secretion by
166% (P = 0.001) and simvastatin decreased total PAI-1 secretion by 64% (P = 0.002). No significant changes were
observed in adiponectin mRNA expression and secretion by dexamethasone and simvastatin, while pre-treatment
with simvastatin reversed dexamethasone induced PAI-1 secretion by 89%, as compared to control levels.
Conclusion: The present study confirmed the suppressive effects of simvastatin on PAI-1 expression and secretion
from bone marrow adipocytes. Furthermore, pre-treatment with simvastatin reversed dexamethasone induced PAI-
1 secretion. Simvastatin may thus exhibit preventive effects against steroid-induced osteonecrosis of the femoral
head by suppressing PAI-1 secretion.
Background
Osteonecrosis of the femoral head (ONFH) is a common
complication of high-dose glucocorticoid treatment. Ster-
oids, such as glucocorticoids, have diverse activities
throughout the body in multiple organs, and numerous
disorders have been linked to hypercortisolism. Abnormal
lipid and protein metabolism, elevated blood glucose, ves-
sel wall weakening and osteoporosis are some of the side
effects attributed to receiving glucocorticoids, while hyper-
coagulation/hypofibrinolysis [1-3], adipogenesis [4,5],
endothelial cell apoptosis [6,7], fat-cell enlargement [8],
and increased intraosseous pressure [9] are thought to be
associated with steroid-induced ONFH.
Recent reports have shown that visceral adipocytes
secrete various physiologically active substances known
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is a large quantity of mature adipocytes that are possible
candidates for adipokine secretion. Considering the
enclosed nature of the bone marrow space, intramedul-
lary adipocytes may be involved in bone metabolism, as
we previously reported that bone marrow adipocytes
express receptor activator of NF-B ligand (RANKL)
and support osteoclast differentiation [12].
Plasminogen activator inhibitor-1 (PAI-1), one of the
adipokines secreted by adipocytes [13,14], suppresses
fibrinolysis by binding tissue-type plasminogen activator
(t-PA), and a relationship between PAI-1 and thrombo-
sis or hypercoagulation has been suggested. Further-
more, blood coagulation in the femoral head is thought
to be associated with osteonecrosis. There are several
reports regarding increased PAI-1 secretion in blood
sera of patients with ONFH [15-18]. We also previously
reported about dexamethasone-induced PAI-1 secretion
from human bone marrow adipocytes [19].
There are several studies indicating that statins, 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, have both lipid-lowering effects and
preventive effects against steroid-induced ONFH [20-23].
However, the detailed mechanisms of these preventive
effects against steroid-induced ONFH are unclear.
T h ep u r p o s eo ft h ep r e s e n ts t u d yi st oe x a m i n et h e
effects of statins on PAI-1 expression and secretion in
primary bone marrow adipocytes in vitro.
Methods
Study subjects
Bone marrow fluid was obtained from the femoral necks
of 40 patients (6 men, 34 women; age range 52-81 years)
undergoing hip joint replacement surgery. Patients with
diabetes mellitus, rheumatoid arthritis, and metabolic
bone disorders and those with a history of glucocorticoid
therapy were excluded. We divided samples into three or
four groups, including the control, dexamethasone and
simvastatin groups. Each experiment was performed with
samples from 6 or 7 patients (n = 6 or 7). The energy sta-
t u si ne a c he x p e r i m e n ti sa sf o l l o w ;F i g u r e1 A ,B :m e a n
BMI, 24.9; mean age, 69.3 years, Figure 2A, B: mean BMI,
23.3; mean age, 64.8 years, Figure 3A, B: mean BMI, 24.4;
mean age, 66.5 years, Figure 4: mean BMI, 23.7; mean
age, 60.3 years. BMI and age were analyzed statistically,
but no significant trends were noted. The study protocol
was approved by the Institutional Ethics Review Board
a n di n f o r m e dc o n s e n tw a so b t a i n e df r o me a c hp a t i e n t
before surgery.
Isolation and culture of primary adipose cells
Bone marrow fluid was mixed with 20 mL of Dulbecco’s
modified Eagle’s medium (DMEM: Gibco BRL, Grand
Island, NY) and treated with 0.1% collagenase A (Sigma
Chemical Co., St. Louis, MO) for 1 h at 37°C. Digested
cells were then centrifuged at 200 × g for 5 min, and the
adipocyte layer was carefully aspirated from the upper
lipid phase [12,19,24]. This procedure includes bone mar-
row collection and complete cell digestion by collagenase
treatment, and because only adipocytes float in the med-
ium, they can be isolated by centrifugation and aspiration
of the floating layer. To purify the isolated adipocytes,
cells were filtered through a 200-μm diameter nylon
mesh, and washed three times with fresh medium. Adi-
pocytes were counted, and 5×10
6 cells were then sus-
pended in 2 mL serum-free DMEM in 15-mL Falcon
tubes and subjected to suspension culture in the presence
of 1 μM dexamethasome (Wako Pure Chemical Industry,
Osaka, Japan) or 10 μM simvastatin (Toronto Research
Chemicals, Toronto ON, Canada) under 5% CO2 at 37°C.
Samples of primary adipose cells and conditioned med-
ium were taken at various times over the course of 48 h.
Analysis of PAI-1 and adiponectin mRNA expression
PAI-1 and adiponectin mRNA expression was measured
by quantitative real-time reverse transcription-polymer-
ase chain reaction (RT-PCR). Total RNA was extracted
from adipocytes using an RNeasy Mini Kit 250 (Qiagen,
Chatsworth, CA) according to the manufacturer’s
instructions. Total RNA (100 ng) was reverse-transcribed
with Taqman One Step PCR Master Mix Reagents kit
(Applied Biosystems, Foster City, CA). Sequences of PCR
primers were PAI-1 (SERPINE1, Hs00167155_m1), adi-
ponectin (ADIPOQ, Hs00605917_m1), and GAPDH
(GAPDH, Hs99999905_m1) (Taqman Gene Expression
Assay, Applied Biosystems; product name, product num-
ber, respectively). PCR assays were conducted using the
ABI PRISM 7000 Sequence Detector System (Applied
Biosystems) according to the manufacturer’s instructions.
Expression of each mRNA was estimated after adjust-
ment for GAPDH mRNA expression.
Analysis of PAI-1 and adiponectin protein secretion
PAI-1 and adiponectin levels in culture medium were
quantified by enzyme-linked immunosorbent assay
(ELISA). The protein levels of total PAI-1 and adiponec-
tin were determined using an LPIA-PAI test (Mitsubishi
Chemical Yatron, Tokyo, Japan) and a human adiponec-
tin ELISA kit (Otsuka Pharmaceutical Co., Ltd., Tokyo,
Japan), respectively.
Statistical analysis
Results are shown as means ± SD. Data were analyzed
using SPSS (Version 16.0). Mann-Whitney test was used
to compare each parameter. P values of < 0.05 were
considered to be statistically significant.
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PAI-1 and adiponectin mRNA expression regulated by
dexamethasone or simvastatin
PAI-1 and adiponectin mRNA expression in bone mar-
row adipocytes were examined by RT-PCR. PAI-1 mRNA
expression was significantly up-regulated by 388% (P =
0.002) with dexamethasone and down-regulated by 45%
(P = 0.002) with simvastatin, as compared to control
levels (Figure 1A), while adiponectin mRNA expression
was 95% with dexamethasone, and 125% with simvastatin
(Figure 1B).
A time-course study of PAI-1 mRNA expression with
1 μM dexamethasone or 10 μM simvastatin was per-
formed. Significant increases in PAI-1 mRNA expression
were observed using dexamethasone. Peak PAI-1 mRNA
expression was 490% (P = 0.001), as compared to con-
trol levels, at 12 h (Figure 2A), and was down-regulated
by 34% (P = 0.001) at 48 h with simvastatin (Figure 2B).
PAI-1 and adiponectin protein secretion regulated by
dexamethasone or simvastatin
Total PAI-1 and adiponectin levels in culture medium
were measured by ELISA after 36 h of suspension
culture. Dexamethasone increased total PAI-1 secretion
by 166% (P = 0.001) and simvastatin decreased total
PAI-1 secretion by 64% (P = 0.002), as compared to
control levels, while pre-treatment with simvastatin
reversed dexamethasone-induced total PAI-1 secretion
by 89% (P = 0.109) (Figure 3A). Dexamethasone and
simvastatin slightly, but not significantly, increased adi-
ponectin secretion. Pre-treatment with 10 μMs i m v a s t a -
tin following 1 μM dexamethasone slightly increased
adiponectin secretion by 110% (P = 0.249), as compared
to control levels (Figure 3B).
A time-course study of total PAI-1 secretion with dexa-
methasone or simvastatin was conducted and the total
PAI-1 in culture medium was measured by ELISA. We
divided bone marrow adipocytes into four groups, and
total PAI-1 protein secretion was determined by ELISA
at 12, 18, 24 and 36 h. The four groups were: untreated
controls; treatment with 1 μM dexamethasone at 12 h;
treatment with 10 μM simvastatin at 0 h; and treatment
with 10 μM simvastatin at 0 h, followed by 1 μMd e x a -
methasone at 12 h. At 24 h and 36 h, dexamethasone
increased total PAI-1 secretion by 136% (58.3 ng/mL: P =
0.002) and 167% (101.5 ng/mL: P = 0.001), respectively,
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Figure 1 Effects of dexamethasone and simvastatin on PAI-1 (A) and adiponectin (B) mRNA expression. Human bone marrow adipocytes
were cultured in serum-free DMEM with 1 μM dexamethasone or 10 μM simvastatin for 24 h. PAI-1 and adiponectin mRNAs extracted from the
floating adipocyte layer were assessed by real-time RT-PCR. Cont.: control group; DEX: dexamethasone-treated group; SIM: simvastatin-treated
group. PAI-1 mRNA expression was up-regulated by dexamethasone and down-regulated by simvastatin. Data represent relative expression levels
vs. control levels and are expressed as means ± SD. *P < 0.05 between two values.
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tatin decreased total PAI-1 secretion by 56.1% (24 ng/
mL: P = 0.002) and 68.3% (41.5 ng/mL: P =0 . 0 0 2 ) ,
respectively, as compared to control levels. Simvastatin
pretreatment following dexamethasone showed no signif-
icant changes at 24 h and 36 h (Figure 4).
Discussion
Steroid-induced ONFH is a severe complication in
patients receiving steroid treatment for rheumatoid
arthritis, collagen diseases, allergies, or after having
undergone transplant surgery. The pathogenesis of
ONFH is unclear, but there is now consensus on the
etiopathogenesis of ONFH, both in terms of intravascu-
lar thrombosis-induced occlusion and extravascular
lipid-deposition-induced pressure, which leads to
impairment of the intra-osseous blood supply [25]. Glu-
cocorticoid also induces intravascular hypercoagulation
and hypofibrinolysis by oxdative stress to endothelial
cells. [6,7]. In contrast, lipid transportation to peripheral
tissue, elevated adipogenesis and enlargement of adipo-
cytes are involved in extravascular events [4,5,8]. It has
been reported that statins prevent the incidence of ster-
oid-induced osteonecrosis and the enlargement of bone
marrow adipocytes in rabbits [26].
Recent studies have shown that visceral adipocytes
secrete various physiologically active substances, known
as adipokines, that play important roles in metabolic
syndrome [10,11,13,14]. However, there are few reports
on bone marrow adipocytes and bone metabolism. We
previously reported that human bone marrow adipocytes
express RANKL and support osteoclast differentiation
[12], and increased PAI-1 secretion from bone marrow
adipocytes induced by dexamethasone [19]. Blood sup-
ply to the femoral head is poor because of its anatomic
structure. Therefore, the biological environment of the
bone marrow in the femoral head may differ from the
external environment of the bone. Taking the enclosed
bone marrow space into consideration, PAI-1 expression
in bone marrow adipocytes may play an important role
in the formation of intravenous thrombi.
The present study demonstrated that dexamethasone
up-regulates PAI-1 expression, while simvastatin down-
regulates it. PAI-1 mRNA expression was significantly
enhanced at 12 h and total PAI-1 secretion was continu-
ously increased when cells were treated with dexametha-
sone. Our results do not contradict previous reports on
increased blood PAI-1 levels and ONFH [15-18]. PAI-1
mRNA expression was gradually suppressed to 38% of
control levels by 48 h and total PAI-1 secretion was
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Figure 2 Time-course study of PAI-1 mRNA expression with dexamethasone or simvastatin. Human bone marrow adipocytes were
cultured in serum-free DMEM with 1 μM dexamethasone (A) or 10 μM simvastatin (B). Total RNA was extracted from the floating adipocyte layer
and PAI-1 mRNA were detected by real-time RT-PCR at 6, 12, 24, 36 and 48 h. PAI-1 mRNA expression was significantly up-regulated by
dexamethasone at 12 h. PAI-1 mRNA expression was gradually down-regulated by simvastatin. Data represent relative expression levels vs.
control levels at identical time points and are expressed as means ± SD. *P < 0.05 vs. untreated control cells at identical time points.
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treatment with simvastatin reversed dexamethasone-
induced PAI-1 protein secretion from bone marrow adi-
pocytes. A hypercoagulated and ischemic state in the
femoral head may occur during increased PAI-1 secre-
tion from bone marrow adipocytes. Therefore, suppres-
sing PAI-1 secretion may be important for preventing
steroid-induced ONFH. Our findings support previous
findings on the protective effects of statins against ster-
oid-induced ONFH [20-23].
Recent reports have shown that statins also have protec-
tive effects against atherosclerosis and metabolic syndrome
[27-32]. In these reports, statins were shown to suppress
PAI-1 mRNA expression in endothelial cells [29-31], visc-
eral and subcutaneous adipocytes [27,28]. PAI-1 mRNA
expression is thought to be activated via the type-1 angio-
tensin II receptor (AT1 receptor) and Rho pathway
[33-35]. As statins suppress the production of metabolic
products, including geranylgeranyl pyrophosphate
(GGPP), from mevalonic acid to cholesterol synthesis, they
may inactivate Rho through the suppression of GGPP
synthesis and down-regulate PAI-1 mRNA expression. In
bone marrow adipocytes, PAI-1 mRNA expression may
also be regulated via the AT1 receptor and Rho pathway.
Low levels of hepatic cytochrome P4503A (CYP3A),
an enzyme that inactivates steroids, have been reported
in patients with ONFH [36,37]. Simvastatin induces
CYP3A activity and prevents the development of ONFH
in patients receiving steroid treatment [38]. Although
we used simvastatin in the present study, it remains
uncertain which statin is most effective in suppressing
PAI-1 secretion from bone marrow adipocytes.
Adiponectin is an important endocrine factor regulat-
ing insulin sensitivity, volume of visceral adipose mass
and lypolysis, and is closely associated with whole body
metabolism [10,11]. Glucocorticoids induce expression
of leptin, particularly in visceral adipocytes obtained
from obese individuals [39], whereas adiponectin is
down-regulated by dexamethasone [40]. In bone marrow
adipocytes, dexamethasone showed no significant effects
on adiponectin and TNF-a secretion in a previous study
[19]. In the present study, no significant effects on adi-
ponectin expression or secretion were observed after
treatment with dexamethasone or simvastatin; however,
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Figure 3 Effects of dexamethasone and simvastatin on total PAI-1 and adiponectin protein secretions after 36 h of suspension culture.
Human bone marrow adipocytes were cultured in serum-free DMEM with 1 μM dexamethasone, 10 μM simvastatin or 10 μM simvastatin
pretreatment following 1 μM dexamethasone at 12 h. ELISA analysis of total PAI-1 protein secretion (A) and adiponectin protein secretion (B)
were performed after 36 h of suspension culture. Cont.: control group, DEX: dexamethasone-treated group, SIM: simvastatin-treated group, SIM
+DEX: simvastatin following dexamethasone-treated group. Total PAI-1 secretion was up-regulated by dexamethasone and down-regulated by
simvastatin. Simvastatin reversed the dexamethasone induced PAI-1 secretion below control levels. Dexamethasone and simvastatin slightly, but
not significantly, increased adiponectin secretion. Data represent relative secretion levels vs. control levels and are expressed as means ± SD. *P
< 0.05 between two values.
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cytes and subcutaneous, visceral adipocytes.
Conclusion
Simvastatin down-regulated PAI-1 mRNA expression
and protein secretion in human bone marrow adipocytes.
Simvastatin also suppressed dexamethasone-induced
PAI-1 secretion in bone marrow adipocytes. Our results
may provide insight into one of the mechanisms by
which simvastatin prevents steroid-induced ONFH.
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